Dual GIP/GLP-1 receptor agonist, FDA- and EMA-approved as Mounjaro and Zepbound. Research-vial tirzepatide is a different, unapproved product, not made or reviewed as those medicines, and not for human use.
Approved-analogue classLyophilised vialAlso known as:Mounjaro · Zepbound
Approximately 5 days (human; Mounjaro prescribing information, section 12.3)
Storage
Lyophilised powder below −15 °C in a tightly closed container, shielded from light; equilibrate the sealed vial to room temperature before opening. Reconstituted vials 2–8 °C.
Sizes
10 mg, 15 mg
What it is
The compound. Origin, research and regulatory reality.
Tirzepatide is a synthetic dual GIP/GLP-1 receptor agonist developed by Eli Lilly: a 39-amino-acid peptide engineered from the native GIP sequence with a fatty-diacid moiety for albumin binding. The FDA approved it as Mounjaro for type 2 diabetes on 13 May 2022 and as Zepbound for chronic weight management on 8 November 2023; Mounjaro is also authorised by the EMA.
The SURPASS trial programme characterised its dual-receptor mechanism and glucose-lowering action in adults with type 2 diabetes, including SURPASS-1 (Rosenstock et al., 2021) and a head-to-head comparison with semaglutide (Frías et al., 2021). The SURMOUNT programme (Jastreboff et al., 2022) studied its effect on body weight in adults with obesity or overweight through the same mechanism.
As Mounjaro and Zepbound, tirzepatide is prescription-only, manufactured and reviewed under FDA and EMA oversight, and its US prescribing information carries a boxed warning for thyroid C-cell tumours observed in rats. Research-use-only tirzepatide vials sold outside that supply chain are not those products and have not been reviewed for safety, effectiveness or quality. The FDA has warned of fraudulently compounded tirzepatide and has warned companies that illegally sold unapproved tirzepatide falsely labelled ‘for research purposes’.
Live vendor register · grouped by strength
Every vendor. Cheapest per mg first, kits listed separately.
TIRZEPATIDE · price per mg
6 listings · unflagged vendors first · Listings data last updated October 2026
CostidesVID-COSTIDES · Kit of 10 · US dispatch · $240 per kit (SKU TR20) · other strengths on pre-order until a lot certificate is published · no returns
20 mgkit of 10
99.63%
Calvert Spectrometry certificate, lab unverifiable (no street address or accreditation; domain registered 2026-09-21) · lot CUS930-T20 · analysed 2026-10-01, reported 2026-10-03 · defects: microbial screen "NO SCREENING (N/A)" with no exception flag; peak widths and heights identical to the GHK-Cu and tesamorelin certificates; PDF created 2026-10-10, after the printed report dateCalvert Spectrometry · Batch CUS930-T20 · Oct 03, 2026 · Verify COA ↗
In stock
Same-day dispatch (paid before 2 PM ET) · standard 2–5 business days
Mounjaro and Zepbound are prescription-only medicines. Research-use-only tirzepatide vials are sold for laboratory research, not human use; RUO labelling does not make personal use or import legal everywhere.
How does research-vial tirzepatide differ from Mounjaro or Zepbound?
The approved pens are manufactured and reviewed under FDA/EMA oversight and carry a boxed thyroid-tumour warning based on reviewed safety data. Research vials come from an unreviewed supply chain with no verified purity or delivery controls.
What should a CoA show for tirzepatide?
HPLC purity, LC-MS mass confirmation matching C225H348N48O68 (MW ~4813), a lot number, an independent third-party lab name and a test date. The FDA has warned of fraudulently labelled compounded tirzepatide products.